High Lp(a): what the HORIZON report means for prevention

You can eat well, stay active and still have high lipoprotein(a). This cholesterol-carrying particle, usually called Lp(a), is largely determined by inheritance. Knowing about it can make cardiovascular prevention more personal, especially when heart disease runs in a family. [4]

That is why researchers have been developing medicines that lower it directly. The September 2026 HORIZON announcement brought an important setback for one approach, while leaving the value of understanding your risk intact. [1] [2]

What Lp(a) tells you

High Lp(a) contributes to plaque buildup in arteries and to narrowing of the aortic valve. It usually causes no symptoms, and a standard cholesterol panel does not include its measurement. A reassuring routine cholesterol result therefore does not answer the Lp(a) question. [4] [5]

Roughly one in five people has a high level, although this varies between populations. A high result is information about risk, not a prediction that a heart attack is inevitable. Blood pressure, smoking, diabetes, LDL cholesterol, age and any existing disease all contribute to the picture.

This distinction is useful because several of those other factors can be changed. Inherited risk gives prevention more direction; it does not make prevention futile.

What HORIZON tested

Pelacarsen targets the molecular instructions used to make one component of Lp(a). HORIZON enrolled 8,323 people who already had cardiovascular disease and high Lp(a). Participants received monthly injections of pelacarsen or placebo alongside their usual care. [3] [6]

The researchers asked whether treatment would reduce a combined measure of cardiovascular death, heart attack, stroke and urgent procedures to restore blood flow in coronary arteries. This made the trial a test of health outcomes, rather than simply a test of whether the drug lowered a blood value.

On September 4, 2026, Novartis reported that Lp(a) fell but the trial did not meet that main goal in the overall population. The announcement therefore did not establish the cardiovascular benefit researchers had hoped to see. [1]

How a useful biological idea can meet a difficult result

A factor can contribute to disease without every treatment that changes it producing the expected benefit. Timing, the people treated and the particular medicine can all matter. HORIZON studied people with established disease; it did not test decades of early prevention in healthy young adults or prevention of aortic-valve disease.

The initial announcement does not explain why the main goal was missed. A complete account of events, treatment exposure and safety will help researchers understand the result. It would be premature to assign a cause or assume that a particular subgroup benefited.

Other approaches, including olpasiran and lepodisiran, are being tested in their own outcome studies. They must show whether their effects on Lp(a) translate into fewer important health events. HORIZON leaves that question open for those treatments. [2]

Why measuring Lp(a) still matters

The 2026 US cholesterol guideline recommends measuring Lp(a) at least once in adulthood. After HORIZON, the National Lipid Association reaffirmed the importance of testing and managing overall risk. [2] [7]

The result can inform how strongly to address LDL cholesterol and other risk factors. It can also prompt a conversation about testing close relatives who share part of your inherited risk.

Keep the laboratory unit with the number. Lp(a) may be reported as particle concentration in nmol/L or as mass concentration in mg/dL. The NLA uses these categories: [8]

Read the column matching your report. The two columns are not a formula for converting your result: a fixed multiplier does not reliably translate every sample between the units. Risk also rises gradually, rather than switching on at one boundary. [5] [9]

What you can act on now

Diet and exercise usually change Lp(a) very little, but they can still improve other parts of cardiovascular health. The practical aim is to reduce your total risk, including appropriate management of LDL cholesterol, blood pressure, diabetes and tobacco exposure. [2] [4]

Established cholesterol treatment should not be judged by this one measurement. Statins can slightly increase Lp(a), yet their cardiovascular benefit is a reason to continue them when indicated. A small increase in Lp(a) alone is not a reason to stop a prescribed statin; discuss treatment changes with your clinician. [5] [7]

At Healthy Longevity Clinic, our approach to evaluating evidence connects a finding with a decision that can improve health. We consider the Lp(a) result alongside family history, existing disease and modifiable risks. Further testing is most useful when it helps decide what to do next.

Bring three questions to a consultation: What does my result mean in the context of my health? Are my current prevention goals appropriate? Should close relatives be tested? Those answers can be useful now, while research develops the next generation of treatments.